The erosion of traditional insulin tracking forces biowearables to pivot toward multi-analyte metabolic companionship.
To defend against the risk of GLP-1 drugs rendering standard continuous glucose monitors obsolete, manufacturers are bundling behavioral coaching and testing secondary biomarkers like ketones and potassium.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Device manufacturers are forced to pivot their CGMs into metabolic and lifestyle companions to capture the booming GLP-1 demographic.
To survive shifts in standard diabetes practices, biowearable manufacturers are aggressively launching multi-analyte products to expand their metabolic profiles.
CGM manufacturers are shifting from legacy insulin tracking to multi-analyte systems monitoring ketones or potassium to remain relevant for GLP-1 users.